利福布汀联合多种药物长效治疗耐多药肺结核的有效性分析

目的：分析利福布汀联合多种药物长效治疗耐多药肺结核的有效性。方法方便选取该院2013年7月—2014年7月收治的90例耐多药肺结核患者，随机分为两组，各45例。两组患者均给予丙硫异烟胺、乙胺丁醇、左氧氟沙星等药物进行基础治疗，研究组与对照组在此基础上分别采用利福布汀与利福喷丁治疗。比较两组病灶吸收率及不良反应发生率。结果研究组病灶吸收率与不良反应发生率分别为71.1%、22.2%，对照组分别为68.9%、20.0%，对比两组病灶吸收率与不良反应发生率差异无统计学意义(P>0.05)。结论给予耐多药肺结核患者利福布汀联合多种药物进行治疗，其疗效与利福喷丁基本一致，具有较好的长效治疗机制。

The Efficiency Analysis of Multi-drug Resistant Tuberculosis by Rifabutin Combine Multiple Drugs for Long-term Treatment

Objective To analyse the effectiveness of multi-drug resistant tuberculosis by rifabutin combine multiple drugs for long-term treatment. Methods Convenient selection to randomly divided the 90 cases of patients with multi-drug resis-tant tuberculosis at our hospital from the July, 2013 to July, 2014 that into two groups, each 45 cases. Two groups was given the protionamide, ethambutol, levofloxacin and other medicine for the basic treatment, the treatment group and the control group was respectively treated by rifabutin and rifapentini. To compared the absorptivity of focus and adverse effects rate of them. Results The absorptivity of focus and adverse effects rate of the treatment group was 71.1% and 22.2%, and the con-trol group was 68.9%and 20.0%, to compared the absorptivity of focus and adverse effects rate of them, there was no statisti-cal significance (P>0.05). Conclusion The curative effect of multi-drug resistant tuberculosis by rifabutin combine multiple drugs for long-term treatment is basically the same as the rifapentini, and that has better long-term treatment mechanism.